IRIS
BILO', Maria Beatrice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.192
AS - Asia 3.842
EU - Europa 3.539
SA - Sud America 673
Continente sconosciuto - Info sul continente non disponibili 327
AF - Africa 132
OC - Oceania 11
Totale 21.716
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.869
SG - Singapore 1.540
RU - Federazione Russa 809
IT - Italia 756
VN - Vietnam 711
HK - Hong Kong 571
BR - Brasile 498
CN - Cina 432
IE - Irlanda 428
DE - Germania 278
FR - Francia 272
SE - Svezia 266
UA - Ucraina 220
GB - Regno Unito 163
IN - India 134
CA - Canada 119
BD - Bangladesh 105
FI - Finlandia 90
AR - Argentina 61
MX - Messico 58
NL - Olanda 51
ES - Italia 47
PL - Polonia 47
JP - Giappone 43
IQ - Iraq 41
ZA - Sudafrica 34
TR - Turchia 31
CI - Costa d'Avorio 30
PH - Filippine 30
VE - Venezuela 26
AT - Austria 25
CO - Colombia 23
PK - Pakistan 23
BE - Belgio 21
EC - Ecuador 21
UZ - Uzbekistan 21
CR - Costa Rica 20
HN - Honduras 20
MA - Marocco 20
IL - Israele 19
SA - Arabia Saudita 19
CW - ???statistics.table.value.countryCode.CW??? 18
GT - Guatemala 18
PR - Porto Rico 17
PY - Paraguay 15
SV - El Salvador 15
NI - Nicaragua 14
TH - Thailandia 14
LT - Lituania 12
TT - Trinidad e Tobago 12
ID - Indonesia 11
JM - Giamaica 11
AE - Emirati Arabi Uniti 10
DZ - Algeria 10
AU - Australia 9
CL - Cile 9
JO - Giordania 9
KR - Corea 9
MY - Malesia 8
TN - Tunisia 8
TW - Taiwan 8
AZ - Azerbaigian 7
BO - Bolivia 7
EG - Egitto 7
GP - Guadalupe 7
KE - Kenya 6
LB - Libano 6
DK - Danimarca 5
KZ - Kazakistan 5
OM - Oman 5
PS - Palestinian Territory 5
RS - Serbia 5
SC - Seychelles 5
UY - Uruguay 5
AL - Albania 4
CZ - Repubblica Ceca 4
MM - Myanmar 4
NG - Nigeria 4
NP - Nepal 4
PE - Perù 4
RO - Romania 4
SI - Slovenia 4
AM - Armenia 3
BG - Bulgaria 3
CH - Svizzera 3
EE - Estonia 3
GR - Grecia 3
HU - Ungheria 3
PA - Panama 3
BH - Bahrain 2
BY - Bielorussia 2
DM - Dominica 2
DO - Repubblica Dominicana 2
GD - Grenada 2
GE - Georgia 2
GY - Guiana 2
HR - Croazia 2
KG - Kirghizistan 2
LY - Libia 2
MD - Moldavia 2
Totale 21.379
Salva come PNG Salva come JPEG
Città #
Ashburn 1.848
Des Moines 1.774
Singapore 1.125
Chandler 1.019
San Jose 719
Hong Kong 557
Fairfield 535
Dallas 530
Jacksonville 462
Dublin 423
Council Bluffs 362
Houston 344
Boardman 278
Wilmington 250
Woodbridge 249
New York 245
Ho Chi Minh City 234
Seattle 222
Cambridge 216
The Dalles 179
Hanoi 173
Princeton 166
Lawrence 164
Los Angeles 159
Lauterbourg 157
San Mateo 142
Ann Arbor 123
Moscow 111
Beijing 108
Milan 100
Redmond 88
Santa Clara 82
San Diego 67
Washington 65
Helsinki 62
Chicago 61
São Paulo 59
Orem 55
Munich 52
Pune 51
Phoenix 42
Rome 40
London 39
Da Nang 38
San Francisco 38
Montreal 36
Tokyo 36
Hefei 34
Warsaw 32
Atlanta 31
Abidjan 30
Nuremberg 30
Buffalo 29
Frankfurt am Main 29
Stockholm 28
Columbus 26
Turku 26
Chennai 25
Denver 25
Brooklyn 23
Miano 23
Toronto 23
Mexico City 22
Haiphong 21
Manchester 21
Ancona 20
Centro 20
Naples 20
Salt Lake City 20
Amsterdam 19
Boston 19
Milwaukee 19
Tashkent 19
Florence 18
Willemstad 18
San José 17
Baghdad 16
Brussels 16
Shanghai 16
Guangzhou 15
San Salvador 15
Charlotte 14
Managua 14
Tampa 14
Falls Church 13
Irving 13
Kilburn 13
Miami 13
Mumbai 13
Norwalk 13
Cedar Knolls 12
Guatemala City 12
Johannesburg 12
Hải Dương 11
Madrid 11
Riyadh 11
Turin 11
Brasília 10
Pittsburgh 10
Shenzhen 10
Totale 14.880
Salva come PNG Salva come JPEG
Nome #
Contraindications to immunotherapy: A global approach 450
Anaphylaxis in Elderly Patients-Data From the European Anaphylaxis Registry 288
Idiopathic anaphylaxis 269
Insights from comparison of serum IgG4 between T2-eosinophilic asthma and eosinophilic granulomatosis with polyangiitis/idiopathic hypereosinophilic syndrome 269
The roadmap for the Allergology specialty and allergy care in Europe and adjacent countries. An EAACI position paper 264
Hymenoptera Venom Allergy: Management of children and adults in clinical practice 250
EAACI guidelines: Anaphylaxis (2021 update) 212
Anaphylaxis 200
ANCA-negative EGPA: only eosinophils without vasculitis? Insights from anti-T2 biologics 196
Diagnosing, managing and preventing anaphylaxis: Systematic review 193
Rhinopharyngoscopy, computed tomography and magnetic resonance imaging 182
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19 179
Anaphylaxis to baobab fruit: The paradox of “natural healthy food” 172
Clinical aspects of hymenoptera venom allergy and venom immunotherapy 170
Basal Tryptase High Levels Associated with a History of Arterial Hypertension and Hypercholesterolemia Represent Risk Factors for Severe Anaphylaxis in Hymenoptera Venom-Allergic Subjects over 50 Years Old 169
Safety and Adherence to Venom Immunotherapy During COVID-19 Pandemic 167
EAACI Molecular Allergology User's Guide 165
Anaphylaxis in children and adolescents: The European Anaphylaxis Registry 163
Development of a model care pathway for the management of Hymenoptera venom allergy: Evidence-based key interventions and indicators 160
Fatal anaphylaxis in Italy: Analysis of cause-of-death national data, 2004-2016 159
Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma 158
Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy) 153
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 152
Risk Factors and Characteristics of Biphasic Anaphylaxis 152
European hornet (Vespa crabro) sting: a new risk factor for life-threatening reaction in hymenoptera allergic patients? 152
Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry 150
Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice? 150
Diagnosis of Immediate-Type ß-Lactam Allergy In Vitro by Flow-Cytometric Basophil Activation Test and Sulfi doleukotriene Production: a Multicenter Study. 149
CAP-Inhibition, Molecular Diagnostics, and Total IgE in the Evaluation of Polistes and Vespula Double Sensitization 148
Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes 148
Allergen immunotherapy for insect venom allergy: protocol for a systematic review 147
Shortness of interval between two stings as risk factor for developing Hymenoptera venom allergy 147
In vivo diagnosis of allergic diseases - allergen provocation tests 145
Efficacy of an air‐cleaning device equipped with a high efficiency particulate air filter in house dust mite respiratory allergy 145
Advances in Hymenoptera venom immunotherapy 145
Allergy to stings and bites from rare or locally important arthropods: Worldwide distribution, available diagnostics and treatment 143
Why are allergens not detected in the bronchoalveolar lavage fluid of patients undergoing fiberoptic bronchoscopy? Possible explanations 143
Is diet partly responsible for differences in COVID-19 death rates between and within countries? 143
Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis 142
Anaphylaxis caused by Hymenoptera stings: from epidemiology to treatment 141
Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy 141
Detection of Gibberellin-Regulated Protein (Peamaclein) Sensitization among Italian Cypress Pollen-Sensitized Patients 141
The role of component-resolved diagnosis in Hymenoptera venom allergy 140
Epidemiology of hymenoptera allergy 140
Large local reactions to Hymenoptera stings: outcome of re-stings in real-life 138
Antigen 5 Allergens of Hymenoptera Venoms and Their Role in Diagnosis and Therapy of Venom Allergy 138
World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis 137
Safety of a 2-day ultrarush immunotherapy in vespid allergic patients: Focus on elevated serum tryptase 135
Shedding Light on the Venom Proteomes of the Allergy-Relevant Hymenoptera Polistes dominula (European Paper Wasp) and Vespula spp. (Yellow Jacket) 135
A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study 135
Prevention and treatment of hymenoptera venom allergy: Guidelines for clinical practice 135
Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry 135
Diagnosis of Hymenoptera venom allergy 134
Phenotype and risk factors of venom-induced anaphylaxis: a case-control study of the European Anaphylaxis Registry 133
Editorial: Anaphylaxis – A Distinct Immunological Syndrome, but How Much Do We Really Understand? 132
Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation? 131
World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings 131
Oxytocin: a likely underestimated risk for anaphylactic reactions in delivering women sensitized to latex 131
Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies 128
Bonifazi F. Epidemiology of Hymenoptera sting anaphylaxis 127
Intraoperative anaphylaxis: verba volant, scripta manent! 127
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper 126
Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal Basal serum tryptase concentrations 126
Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients 126
Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper 125
Immunotherapy for hymenoptera venom allergy: too expensive for European health care? 124
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients 124
Congruence between international guidelines and mite specific immunotherapy prescribing practices 123
Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper 123
Common Variable Immunodeficiency in Elderly Patients: A Long-Term Clinical Experience 123
International consensus on (ICON) anaphylaxis 122
Hyposensitization therapy of Parietaria-sensitive patients with a tyrosine adsorbed allergoid, Pollinex Parietaria (Bencard Parietaria) 122
EAACI anaphylaxis guidelines: Systematic review protocol 121
2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis 121
World Allergy Organization anaphylaxis guidelines: Summary 120
Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase 120
EAACI Molecular Allergology User's Guide 2.0. 119
Efficacy of a single dose of omalizumab for the prevention of ethylene oxide intraoperative anaphylaxis 119
Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control? 119
Hymenoptera Venom Immunotherapy: How to Safely Switch to the Same Venom From a Different Manufacturer 118
Anisakis hypersensitivity in Italy: prevalence and clinical features: a multicenter study. 118
Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI position paper 117
The dilemma of the negative skin test reactors with a history of venom anaphylaxis: will this always be the case? 117
Efficacy of mepolizumab in patients with concomitant severe eosinophilic asthma and severe chronic urticaria: an example of personalized medicine? 117
A narrative review on asthma and pest sensitization (cockroach, mouse and rat allergens): a social issue besides the medical problem. 116
High adherence to hymenoptera venom subcutaneous immunotherapy over a 5-year follow-up: A real-life experience 116
Insect sting anoxic encephalopathy after stopping venom immunotherapy. 116
COVID-19 lockdown, personal protective equipment, hyper-hygiene and allergy 116
Ves v 5 can establish the diagnosis in patients without detectable specific IgE to wasp venom and a possible north-south difference in Api m 1 sensitization in Europe 115
Lysozyme, a new allergen in donkey's milk 114
High long-term efficacy of venom immunotherapy after discontinuation 114
Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity 114
A case of fatal biphasic anaphylaxis secondary to multiple stings: adrenalin and/or a longer observation time could have saved the patient? 113
The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts 113
Adherence to the rhinitis management plan of allergic rhinitis 112
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy 112
The natural history and epidemiology of insect venom allergy: clinical implications 111
Mast cell diseases and the severity and course of intraoperative anaphylaxis 110
Platelet-activating factor acetylhydrolase: A biomarker in Hymenoptera venom allergy? 110
Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry 109
Totale 14.655
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.553
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 105.553
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022851 0 0 0 0 21 69 46 94 106 75 132 308
2022/20234.055 228 212 169 261 177 1.998 1 167 588 23 166 65
2023/20241.392 268 39 119 139 223 271 23 46 7 53 19 185
2024/20252.735 100 232 100 74 63 174 207 94 809 210 257 415
2025/20266.946 342 397 414 512 711 545 1.416 768 674 598 272 297
2026/20272.632 503 346 480 1.115 188 0 0 0 0 0 0 0
Totale 21.716